The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 07, 2010
Filed:
Aug. 19, 2004
Jaromir Pastorek, Bratislava, SK;
Silvia Pastorekova, Bratislava, SK;
Miriam Zatovicova, Bratislava, SK;
Jan Zavada, Prague, CZ;
Marta Ortova Gut, Prague, CZ;
Zuzanna Zavadova, Prague, CZ;
Jaromir Pastorek, Bratislava, SK;
Silvia Pastorekova, Bratislava, SK;
Miriam Zatovicova, Bratislava, SK;
Jan Zavada, Prague, CZ;
Marta Ortova Gut, Prague, CZ;
Zuzanna Zavadova, Prague, CZ;
Institute of Virology of the Slovak Academy of Sciences, Bratislava, SK;
Abstract
Disclosed herein is the discovery of a soluble MN/CA IX (s-CA IX) found in body fluids, such as, urine and serum. Soluble CA IX comprises the extracellular domain of CA IX or portions thereof. The predominant s-CA IX species is the extracellular domain comprising a proteoglycan-like (PG) domain and carbonic anhydrase (CA) domain, and having a molecular weight of about 50/54 kilodaltons. Diagnostic/prognostic methods for precancer/cancer that detect or detect and quantitate s-CA IX in body fluids, are described. Also disclosed is the coexpression of CA IX and HER-that provides potentially synergistic diagnostic/prognostic and therapeutic strategies for precancer/cancer. Further disclosed are new MN/CA IX-specific antibodies generated from MN/CA IX-deficient mice, useful diagnostically/prognostically and therapeutically for cancer/precancer. Preferred are new antibodies, specific for non-immunodominant epitopes of MN/CA IX, are useful to detect soluble CA IX (s-CA IX) in body fluids, preferably in combination with antibodies specific to immunodominant epitopes of MN/CA IX.